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Abstract
The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a
salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/
proguanil prophylaxis, is reported. The potential interactions between atovaquone/proguanil and these anti-
retroviral drugs are investigated. Pharmacokinetic analyses documented a marked increase in etravirine and
saquinavir plasma concentrations (+55% and +274%, respectively), but not in raltegravir and maraviroc plasma
concentrations. The evidence that atovaquone/proguanil significantly interacts with etravirine and saquinavir, but
not with raltegravir and maraviroc, suggests that the mechanism of interaction is related to cytochrome P450.
Background
Atovaquone/proguanil (Malarone®) is a fixed-dose com-
bination of the anti-malarial agents atovaquone and pro-
guanil hydrochloride. HIV-infected travellers in malaria
endemic countries frequently use atovaquone/proguanil
as a prophylaxis.
Atovaquone displays linear pharmacokinetic with a
mean absolute bioavailability of 23%. It is highly pro-
tein-bound (> 99%) but does not displace other highly
protein-bound drugs in vitro [1]. The principal excretion
route is the liver, with the 94% of the drug excreted
unchanged in the faeces. The elimination half-life is 2-3
days in adults [1].
Proguanil is rapidly absorbed from the gastrointestinal
tract and achieves peak plasma concentrations in 2-4
hours, with an absolute bioavailability as high as 60%
[1]. It is 75% protein bound, and this binding is unaf-
fected by the presence of atovaquone and vice versa [1].
Proguanil is metabolized to cycloguanil (primarily
trough CYP2C19) and 4-chlorophenylbiguanide, with
between 40% and 60% of proguanil excreted renally.
The elimination half-life of proguanil is 12-21 hours [1].
Drug interactions between atovaquone/proguanil and
tetracycline, metoclopramide, rifampin, rifabutin and
warfarin have been described. The concomitant adminis-
tration of indinavir is associated with a 23% decrease in
indinavir Cmin (90% CI 8-35%). Potential interactions
between proguanil and other drugs that are CYP2C19
substrates or inhibitors are unknown [1].
Case presentation
A 32-year-old Caucasian female was admitted to the “L.
Spallanzani” National Institute for Infectious Diseases in
Rome for multi-drug resistant HIV-1 subtype B infection
(diagnosed in 1985), beta-thalassaemia, severe pulmonary
hypertension, wasting syndrome and ritonavir allergy. In
October 2007, a genotypic resistance test (GRT) revealed
high-level resistance to all currently available anti-retrovir-
als (ARVs) and a salvage treatment with unboosted daru-
navir (600 mg bid), lamivudine (300 mg qd) and
raltegravir (400 mg bid) was started. Three months later, a
viral rebound occurred; a new GRT evidenced the emer-
gence of primary N155H/N and secondary D232N muta-
tions in integrase gene with no new RT and PR-related
mutations. In March 2008, after the viral tropism assay, a
new ARV regimen including raltegravir (400 mg bid),
saquinavir (1000 mg bid), maraviroc (150 mg bid) and
etravirine (200 mg bid) was started. Viremia immediately
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decreased to below the detection limit (50cp/ml) and
remained undetectable. Tolerability was good and no
grade 3/4 adverse events have been reported.
In September 2009, the patient planned to spend a
two-week holiday in Kenya. The CD4 cell count was
334/mmc. Standard malaria prophylaxis with atova-
quone/proguanil fixed-dose combination (250/100 mg)
was prescribed: one tablet daily starting two days before
the journey and ending the treatment seven days after
return to Italy [2]. A 12 hour-PK of anti-retrovirals was
performed before starting prophylaxis with atovaquone/
proguanil (Figure 1). The samples were collected in fast-
ing status following this order: the first sample 12 hours
after the last dose of anti-retrovirals (pre-dose); the sec-
ond sample one hour after breakfast and anti-retrovirals
consumption; the following samples at 2, 4, 6 and 12
hours post anti-retrovirals’ intake. The second PK for
the determination of anti-retrovirals’ plasma concentra-
tions during atovaquone/proguanil prophylaxis was col-
lected at day 20 on prophylaxis with the same timing
plan (Figure 1). In order to avoid any food interference
with the PK results, the same diet was administered in
both the PK sampling days. During the stay in Kenya,
the adherence was monitored by self-reported diary that
documented an adherence level of 100% both for anti-
retroviral and prophylaxis drugs. This data was retro-
spectively confirmed by pills count system.
Twenty days after atovaquone/proguanil was started,
the blood examinations documented a CD4 count of
438 cell/mmc, with undetectable HIV-RNA. Liver and
haematological parameters were normal. No clinical or
laboratory adverse events were reported during or after
the journey.
Conclusions
In a recent study, Van Luin et al demonstrated that geo-
metric mean ratios (95% confidence interval) of the area
under the curve (AUC) of atovaquone in patients on efa-
virenz, lopinavir/ritonavir and atazanavir/ritonavir com-
pared with healthy volunteers were 0.25 (0.16-0.38), 0.26
(0.17-0.41) and 0.54 (0.35-0.83), respectively. Proguanil
plasma concentrations were also significantly lower (38-
43%). No data on anti-retroviral pharmacokinetics during
atovaquone/proguanil prophylaxis were provided. The
authors concluded that physicians should be alert to ato-
vaquone/proguanil prophylaxis failures in patients taking
efavirenz, lopinavir/ritonavir or atazanavir/ritonavir [3].
The anti-retrovirals’ pharmacokinetic during atovaquone/
proguanil prophylaxis were analysed. A marked increase
in etravirine and saquinavir AUC0-12h (+55% and +274%,
respectively) and a slight decrease in raltegravir and mara-
viroc AUC0-12h (-23% and -9%, respectively) were docu-
mented. Although AUCs between pre- and post-
prophylaxis are not very different, in the PK profiles of
? AUC0-12h: -23% 
? AUC0-12h: -9%
? AUC0-12h: +55% 
? AUC0-12h: +274% 
Figure 1 Plasma concentrations of antiretroviral drugs (raltegravir, maraviroc, etravirine and saquinavir) evaluated as Area Under
Curve (AUC) before starting atovaquone/proguanil (pre) and at day 20 of prophylaxis (post). The D AUC0-12h represents the difference
in AUC0-12h (during prophylaxis AUC minus pre-prophylaxis AUC). An HPLC-UV method for the simultaneous quantification of the HIV integrase
inhibitor raltegravir, the new non- nucleoside reverse transcriptase inhibitor etravirine, protease inhibitor saquinavir and CCR-5 inhibitor maraviroc
was used [11,12].
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maraviroc and raltegravir the Tmax and the Cmax in post-
prophylaxis appear to be earlier than in pre- prophylaxis,
suggesting a more fast absorption of both drugs. Unfortu-
nately, it was not possible to determine atovaquone and
proguanil plasma concentrations. However, the absence of
established minimum effective atovaquone plasma con-
centrations in the setting of malaria prophylaxis makes it
difficult to assess the clinical relevance of dosing atova-
quone and proguanil plasma concentrations, except for
the evaluation of potential interactions with anti-retroviral
drugs [3]. The evidence that atovaquone/proguanil signifi-
cantly interacts with etravirine and saquinavir, but not
with raltegravir and maraviroc, suggests that the mechan-
ism of interaction is related to cytochrome P450. Etravir-
ine is metabolized primarily by hydroxylation through
several cytochrome P-450 isoenzymes (mainly CYP3A,
CYP2C9 and CYP2C19), followed by glucuronidation of
the metabolites. It is also an inducer of CYP3A and a mild
inhibitor of CYP2C9, 2C19 and P-glycoprotein [4]. Saqui-
navir is metabolized by CYP3A4. It is neither an inducer
nor an inhibitor of P450 system, but it is substrate and
inhibitor of P-glycoprotein and MRP1 [5,6]. Raltegravir is
metabolized via UGT1A1-mediated glucuronidation and is
neither an inducer nor an inhibitor of the CYP oxidation
system or P-glycoprotein [7]. Maraviroc is extensively
metabolized by CYP3A4 and it is a substrate for P-glyco-
protein. At higher doses, maraviroc is a potential inhibitor
of CYP2D6 and perhaps of P-glycoprotein [8]. In vitro,
maraviroc was not found to inhibit any major CYP isoen-
zyme, including CYPIA2, CYP2B6, CYP2C8, CYP2C19,
CYP2D6, and CYP3A4 [9]. Basing on the pharmacokinetic
characteristics of these anti-retrovirals, it is supposable
that atovaquone, or more likely proguanil, interferes with
etravirine and saquinavir for CYP450 mediated metabo-
lism (perhaps on the 2C isoenzymes) with a consequent
marked increase in plasma concentrations of both anti-ret-
rovirals. Despite of the clear effect in plasma concentra-
tions of etravirine and saquinavir, in this case the patient
noticed no side effects, and blood examinations during
prophylaxis documented any lab toxicities. It is possible
that, in this case, the absence of drug-related toxicity was
due to the use of unboosted protease inhibitor; while for
etravirine there are no clear data on the correlation
between PK and toxicity [10].
This case should alert the physicians to be cautious
and vigilant when atovaquone/proguanil prophylaxis is
prescribed in patients treated with etravirine and/or
saquinavir (especially if ritonavir-boosted).
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